Aspirin

Aspirin

SCHEMBL7580

CC(=O)Oc1ccccc1C(=O)O.CC(=O)Oc1ccccc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 1/20 1.00
PTGS2 known ✓ P35354 1/20 1.00
KDM4E B2RXH2 11/20 1.00
HSD17B10 Q99714 9/20 1.00
ALDH1A1 P00352 8/20 1.00
HPGD P15428 7/20 1.00
ESR1 P03372 1/20 1.00
ITGB3 P05106 1/20 1.00
ITGA2B P08514 1/20 1.00
HMGB1 P09429 1/20 1.00
TSHR P16473 1/20 1.00
GGT1 P19440 1/20 1.00
BLM P54132 1/20 1.00
NAPRT Q6XQN6 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
LMNA P02545 1/20 0.86
CYP1A2 P05177 1/20 0.86
CYP2C9 P11712 1/20 0.86
MAPK1 P28482 1/20 0.70
MAPT P10636 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aspirin SCHEMBL1331740 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL1353 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL29350479 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL10456693 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL21722099 0.98 KDM4E (0.96) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL20484785 0.98 KDM4E (0.96) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL4303603 0.98 KDM4E (0.96) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL21488922 0.98 KDM4E (0.96) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL21328429 0.98 KDM4E (0.96) KDM4EHSD17B10ALDH1A1HPGDESR1
Aspirin SCHEMBL7762350 0.98 KDM4E (0.96) KDM4EHSD17B10ALDH1A1HPGDESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250017846-A1 TOPICAL ANALGESICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-01-16 US claimed
US-20230190499-A1 ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE ELIXIR MEDICAL CORPORATION (US) 2023-06-22 US claimed
WO-2018183089-A1 COMPOSITIONS FOR TREATING AND/OR PREVENTING CANCER BOSTON BIOMEDICAL, INC. (US) 2018-10-04 WO claimed
US-20160250217-A1 CRYSTALLINE FORM OF PEMIROLAST RSPR PHARMA AB (SE) 2016-09-01 US claimed
WO-2016109361-A2 3-FLUORO-BENZONITRILE INHIBITORS OF 11-BETA-HYDROXYLASE AUSPEX PHARMACEUTICALS, INC. (US) 2016-07-07 WO claimed
US-20120329813-A1 Pemirolast for the Treatment of Systemic Low Grade Inflammation CARDOZ AB (SE) 2012-12-27 US claimed
EP-2498779-A1 PEMIROLAST FOR THE TREATMENT OF SYSTEMIC LOW GRADE INFLAMMATION Cardoz AB (SE) 2012-09-19 EP claimed
US-20120157415-A1 New Crystalline Form of Pemirolast CARDOZ AB (SE) 2012-06-21 US claimed
WO-2010146348-A9 CRYSTALLINE FORM OF PEMIROLAST CARDOZ AB (SE) 2012-05-03 WO claimed
EP-2443120-A2 NEW CRYSTALLINE FORM OF PEMIROLAST Cardoz AB (SE) 2012-04-25 EP claimed
WO-2011058331-A1 PEMIROLAST FOR THE TREATMENT OF SYSTEMIC LOW GRADE INFLAMMATION CARDOZ AB (SE) 2011-05-19 WO claimed
US-20110112188-A1 Treatment of Inflammatory Conditions DYNAMIS THERAPEUTICS, INC. 2011-05-12 US claimed
US-20110071767-A1 Hepatotoxicity Molecular Models OCIMUM BIOSOLUNTIONS, INC. (IN) 2011-03-24 US claimed
WO-2011027119-A1 COMBINATION MEDICAMENT SHAH, SUNIL (GB) 2011-03-10 WO claimed
US-20110002990-A1 BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF ALTER DOMUS (US) LLC 2011-01-06 US claimed
WO-2010146348-A2 NEW CRYSTALLINE FORM OF PEMIROLAST CARDOZ AB (SE) 2010-12-23 WO claimed
WO-2010146341-A2 NEW CRYSTALLINE FORM OF PEMIROLAST CARDOZ AB (SE) 2010-12-23 WO claimed
US-20100124550-A1 AMIDE INHIBITORS OF RENIN AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-20 US claimed
WO-2009007679-A2 COMBINATION FOR USE IN THE TREATMENT OF ATHEROSCLEROSIS COMPRISING A MAST CELL INHIBITOR AND A THROMBOXANE A2 ANTAGONIST CARDOZ AB (SE) 2009-01-15 WO claimed
US-7300666-B2 Mixture for transdermal delivery of low and high molecular weight compounds JRX BIOTECHNOLOGY, INC. (US) 2007-11-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100124550-A1 AMIDE INHIBITORS OF RENIN REN, ACE, AGTR2 PTGS1 355/4885PTGS2 464/4885KDM4E 2631/4885
US-20250017846-A1 TOPICAL ANALGESICS OPRK1, OPRL1, OPRM1 PTGS1 113/4885PTGS2 127/4885KDM4E 4409/4885
US-20110002990-A1 BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF CYP2B6, CYP3A43, CYP2D6 PTGS1 428/4885PTGS2 599/4885KDM4E 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.